echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Claudin 18.2 of Chuangsheng Group Completed the First Patient Dosing in Phase IIa Clinical Trial

    Claudin 18.2 of Chuangsheng Group Completed the First Patient Dosing in Phase IIa Clinical Trial

    • Last Update: 2022-05-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 28, Chuangsheng Group announced that its Claudin18.


    Biliary tract cancer is a rarer malignancy, including bile duct cancer and gallbladder cancer


    This study is an open-label, single-arm, multicenter Phase IIa clinical study in patients with locally advanced or metastatic biliary tract cancer who have not received systemic therapy to evaluate the safety, tolerability, and antibacterial properties of TST001.


    TST001 is a high-affinity humanized monoclonal antibody targeting Claudin18.


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.